Psychedelic-focused venture studio Beckley Waves has acquired digital ketamine-assisted therapy (KAT) provider Nue Life.
Beckley Waves seeks to improve access to well-being-enhancing medicines and tools in an industry that is dominated by “antiquated” approaches to mental health, according to Daniel Love, co-founder and partner at Beckley Waves and interim CEO of Nue Life.
“At the end of the day, ketamine-assisted therapy is really the only [psychedelic] that’s widely accessible and legal, at least at a federal level,” Love told Behavioral Health Business. “So if we want to help people now, this is what’s possible, and we think is quite compelling.”
Miami, Florida-based Nue Life leverages sublingual ketamine doses in combination with an app and virtual after-care programs to treat patients across 23 states. Rapid-dissolve ketamine tablets have been demonstrated to be a safe and effective therapy for treatment-resistant depression and anxiety.
Nue Life, which has treated over 10,000 patients, recently pivoted from an exclusively direct-to-consumer approach to a diversified strategy by adding B2B offerings through its new partnership program Nue Network.
The company sets itself apart from other KAT providers, in part, through its more cost-effective digital model.